As we sought to characterize irAEs in patients treated with anti-PD-1 ICI singly, we restricted our analyses to melanoma patients which limits the generalizability of these results to other histologies and patients treated with combinations including ICI/chemotherapy and ICI combinations. The gene discussed is PDCD1; the disease is melanoma.